nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

09.04.2022 | Editorial

Total-body [¹⁸F]FDG PET/CT scan has stepped into the arena: the faster, the better. Is it always true?

verfasst von: Luca Filippi, Orazio Schillaci

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Excerpt

Technological development has always represented the essential core of nuclear medicine advancement. In particular, the introduction of hybrid imaging, combining morphological and functional data in a unique approach [1, 2], has definitely constituted a cornerstone culminated, more than twenty-two years ago, with the nomination of positron emission computed tomography (PET/CT) as the medical invention of the year 2000 by the Time Magazine. Since then, PET/CT has gained a well-established role in diagnosis, staging, and monitoring the response to treatment in many oncological conditions. …

Hricak H, Choi BI, Scott AM, Sugimura K, Muellner A, von Schulthess GK, Reiser MF, Graham MM, Dunnick NR, Larson SM. Global trends in hybrid imaging. Radiology. 2010;257:498–506. https://doi.org/10.1148/radiol.10100579.CrossRefPubMed

Kjaer A. Hybrid imaging with PET/CT and PET/MR. Cancer Imaging. 2014;14(S1):O32. https://doi.org/10.1186/1470-7330-14-S1-O32.CrossRefPubMedCentral

Schillaci O, Urbano N. Digital PET/CT: a new intriguing chance for clinical nuclear medicine and personalized molecular imaging. Eur J Nucl Med Mol Imaging. 2019;46:1222–5. https://doi.org/10.1007/s00259-019-04300-z.CrossRefPubMed

Siekkinen R Kirjavainen AK Koskensalo K Smith NAS Fenwick A Saunavaara V et al. Assessment of a digital and an analog PET/CT system for accurate myocardial perfusion imaging with a flow phantom. J Nucl Cardiol. 2021. https://doi.org/10.1007/s12350-021-02631-9

Filippi L, Schillaci O. Digital PET and detection of recurrent prostate cancer: what have we gained, and what is still missing? Expert Rev Med Devices. 2021;18:1107–10. https://doi.org/10.1080/17434440.2021.1990036.CrossRefPubMed

Alberts I, Sachpekidis C, Prenosil G, Viscione M, Bohn KP, Mingels C, et al. Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [18F]-FDG PET/CT. Ann Nucl Med. 2021;35:485–92. https://doi.org/10.1007/s12149-021-01588-6.CrossRefPubMedPubMedCentral

Lasnon C, Coudrais N, Houdu B, Nganoa C, Salomon T, Enilorac B, Aide N. How fast can we scan patients with modern (digital) PET/CT systems? Eur J Radiol. 2020;129:109144. https://doi.org/10.1016/j.ejrad.2020.109144.CrossRefPubMed

Lan X, Younis MH, Li K, Cai W. First clinical experience of 106 cm, long axial field-of-view (LAFOV) PET/CT: an elegant balance between standard axial (23 cm) and total-body (194 cm) systems. Eur J Nucl Med Mol Imaging. 2021;48:3755–9. https://doi.org/10.1007/s00259-021-05505-x.CrossRefPubMedPubMedCentral

Katal S, Eibschutz LS, Saboury B, Gholamrezanezhad A, Alavi A. Advantages and applications of total-body PET scanning. Diagn Basel. 2022;12:426. https://doi.org/10.3390/diagnostics12020426.CrossRef

10.

Saboury B, Morris MA, Farhadi F, Nikpanah M, Werner TJ, Jones EC, et al. Reinventing molecular imaging with total-body PET. Part I Pet Clin. 2020;15:427–38. https://doi.org/10.1016/j.cpet.2020.06.012.CrossRefPubMed

11.

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma Nat Rev Dis Primers. 2021;7:6. https://doi.org/10.1038/s41572-020-00240-3.CrossRefPubMed

12.

Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China. Liver Cancer. 2013;2:31–9. https://doi.org/10.1159/000346220.CrossRefPubMedPubMedCentral

13.

Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912–21. https://doi.org/10.2967/jnumed.108.055087.CrossRefPubMed

14.

Filippi L, Schillaci O, Bagni O. Recent advances in PET probes for hepatocellular carcinoma characterization. Expert Rev Med Devices. 2019;16:341–50. https://doi.org/10.1080/17434440.2019.1608817.CrossRefPubMed

15.

Zucchetta P, Lacognata C, Girardi F, Spimpolo A, Crimì F, Cabrelle G, et al. [18F]FDG PET/MRI in the follow-up of hepatocellular carcinoma after liver transplantation. Nucl Med Commun. 2022;43:359–67. https://doi.org/10.1097/MNM.0000000000001518.CrossRefPubMed

16.

Filippi L, Di Costanzo GG, Tortora R, Pelle G, Saltarelli A, Marino Marsilia G, Cianni R, et al. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization. Nucl Med Commun. 2020;41:78–86. https://doi.org/10.1097/MNM.0000000000001123.CrossRefPubMed

17.

Hu Y Liu G Yu H Gu J Shi H. Diagnostic performance of total-body 18F-FDG PET/CT with fast 2-min acquisition for liver tumours: comparison with conventional PET/CT. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05772-2

18.

Spencer BA, Berg E, Schmall JP, Omidvari N, Leung EK, Abdelhafez YG, et al. Performance evaluation of the uEXPLORER total-body PET/CT scanner based on NEMA NU 2–2018 with additional tests to characterize PET scanners with a long axial field of view. J Nucl Med. 2021;62:861–70. https://doi.org/10.2967/jnumed.120.250597.CrossRefPubMedPubMedCentral

19.

Hu P, Zhang Y, Yu H, Chen S, Tan H, Qi C, Dong Y, et al. Total-body 18F-FDG PET/CT scan in oncology patients: how fast could it be? Eur J Nucl Med Mol Imaging. 2021;48:2384–94. https://doi.org/10.1007/s00259-021-05357-5.CrossRefPubMed

20.

Alberts I, Hünermund JN, Prenosil G, Mingels C, Bohn KP, Viscione M, et al. Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. Eur J Nucl Med Mol Imaging. 2021;48:2395–404. https://doi.org/10.1007/s00259-021-05282-7.CrossRefPubMedPubMedCentral

21.

Hirmas N, Leyh C, Sraieb M, Barbato F, Schaarschmidt BM, Umutlu L, et al. 68Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma. J Nucl Med. 2021;62:1235–41. https://doi.org/10.2967/jnumed.120.257915.CrossRefPubMedPubMedCentral

22.

Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Privé BM, et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 2021;48:4350–68. https://doi.org/10.1007/s00259-021-05433-w.CrossRefPubMedPubMedCentral

23.

Sui X, Tan H, Yu H, Xiao J, Qi C, Cao Y, et al. Exploration of the total-body PET/CT reconstruction protocol with ultra-low 18F-FDG activity over a wide range of patient body mass indices. EJNMMI Phys. 2022;9(17):15. https://doi.org/10.1186/s40658-022-00445-3.CrossRef

Titel: Total-body [18F]FDG PET/CT scan has stepped into the arena: the faster, the better. Is it always true?
verfasst von: Luca Filippi
Orazio Schillaci
Publikationsdatum: 09.04.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05791-z

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Cervical lymph node staging in head and neck tumors: bridging the gap between humans and companion animals

Lymphopenia in patients affected by SARS-CoV-2 infection is caused by margination of lymphocytes in large bowel: an [18F]FDG PET/CT study

Quantitative assessment of myelin density using [11C]MeDAS PET in patients with multiple sclerosis: a first-in-human study

[68 Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease

Evidence-based guideline of the European Association of Nuclear Medicine (EANM) on imaging infection in vascular grafts

Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer